Navigation Links
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Date:9/11/2009

d in Paris (EURONEXT PARIS: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to

ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Forward Looking Statement - sanofi-aventis

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
2. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
3. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
4. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
5. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
8. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
9. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
10. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
11. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...   Mary,s Medicinals today announced that its ... Sponsor of Operation Grow4Vets , a national, nonpartisan ... and services to assist them in living with injuries ... , An ever-increasing number of medical studies ... treatment for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic ...
(Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
Breaking Medicine Technology:Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... and additional analyses from the Phase II portion of ... relaxin for the treatment of acute heart failure will ... meeting of the Heart Failure Association of the European ... M.D., professor of cardiology at the University of Brescia, ...
... Breast Cancer and Melanoma Studies - Conference Call to ... am BRANFORD, Conn., May 28 CuraGen Corporation ... for three data presentations from its ongoing clinical trials ... patients with advanced breast cancer and melanoma at the ...
Cached Medicine Technology:Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, Fancyflyingfox.com, ... special occasion clothes, has announced its latest designs of ... addition, all the new elegant outfits are offered with ... place an order before October 30 can enjoy this ... and great marketing strategies, it has become one of ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... more than 600,000 people die of sudden cardiac arrest in ... heart attack or a heart rhythm disturbance. ,When medical ... in which the heart's main pumping chambers flutter wildly and ... survive to go home. ,About 30 percent of victims, ...
... sometimes switch to lower tar cigarettes in hopes of ... experience the consequences of higher tar cigarettes.// ,Non-filter cigarettes ... the United States and United Kingdom. A new study ... for people who smoke medium-tar cigarettes, low-tar cigarettes, or ...
... recent study researchers have created a model of the human ... may be a precursor to Alzheimer’s.// Myelin is ... allows for messages to be sent through the brain. However, ... promote the production of a toxic protein that attacks the ...
... destroys T-cells in the immune system. According to the ... 800,000 and 900,000 people living with HIV.// ,Previous ... be infected with HIV, and a new study helps ... of human foreskin. They found each sample contained cells ...
... doctors treat certain prostate cancer patients.The three strongest predictors ... grade, PSA level and pathologic stage. //The summation of ... system or a Gleason score (GS). The most common ... In a new study, researchers look to understand the ...
... molecule may have the potential to protect the kidneys ... ,For the study, mice were genetically engineered to ... factor (HGF) or another natural factor called parathyroid hormone-related ... functions, thus allowing the researchers to study how the ...
Cached Medicine News:Health News:Vasopressin Found To Boost Survival In Sudden Cardiac arrest 2Health News:New Hope for Kidney Failure 2
Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
Near point card/newspaper 8 to 48 point type 5 1/2" X 8"....
Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w...
... provides references to many common print sizes, from ... size. This provides the examiner a starting point ... with black ink on yellow styrene for increased ... 20/20. Other notations include Jaeger, M notation, lower ...
Medicine Products: